Last updated on August 2009

Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis


Brief description of study

The purpose of this study is to establish whether RA patients with moderate to severe disease activity with unsustainable response to infliximab 3 mg/kg every 8 weeks have better efficacy with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.

Clinical Study Identifier: NCT00216177

Find a site near you

Start Over